Leerink Partnrs Reiterates “Outperform” Rating for XOMA (NASDAQ:XOMA)

Leerink Partnrs reaffirmed their outperform rating on shares of XOMA (NASDAQ:XOMA) in a report published on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for XOMA’s Q1 2024 earnings at ($0.85) EPS, Q2 2024 earnings at ($0.79) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.69) EPS, FY2024 earnings at ($2.87) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $3.31 EPS.

Several other equities analysts have also recently issued reports on the company. HC Wainwright reissued a buy rating and set a $74.00 target price on shares of XOMA in a research note on Wednesday. SVB Leerink assumed coverage on XOMA in a research note on Monday. They set an outperform rating and a $40.00 target price on the stock.

XOMA Price Performance

Shares of XOMA stock opened at $25.44 on Monday. The company has a debt-to-equity ratio of 1.34, a current ratio of 8.68 and a quick ratio of 8.68. The business’s 50 day simple moving average is $25.10 and its two-hundred day simple moving average is $20.71. The stock has a market capitalization of $296.12 million, a P/E ratio of -6.30 and a beta of 0.57. XOMA has a one year low of $13.48 and a one year high of $27.00.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. The company had revenue of $1.83 million during the quarter, compared to analysts’ expectations of $1.01 million. Analysts forecast that XOMA will post -1.73 EPS for the current year.

Institutional Investors Weigh In On XOMA

An institutional investor recently raised its position in XOMA stock. BNP Paribas Financial Markets lifted its position in shares of XOMA Co. (NASDAQ:XOMA) by 55.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,543 shares of the biotechnology company’s stock after purchasing an additional 1,266 shares during the quarter. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.